IceCure Medical (NASDAQ:ICCM) Rating Reiterated by HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of IceCure Medical (NASDAQ:ICCM) in a report published on Tuesday, Benzinga reports. They currently have a $3.00 price target on the stock.

Separately, Alliance Global Partners upped their target price on IceCure Medical from $1.90 to $2.90 and gave the stock a buy rating in a report on Wednesday, March 20th.

IceCure Medical Price Performance

Shares of ICCM opened at $1.23 on Tuesday. IceCure Medical has a 12-month low of $0.52 and a 12-month high of $1.57. The business has a 50-day simple moving average of $1.28 and a two-hundred day simple moving average of $1.11. The company has a quick ratio of 3.08, a current ratio of 3.66 and a debt-to-equity ratio of 0.03. The stock has a market cap of $56.11 million, a PE ratio of -3.73 and a beta of 0.73.

IceCure Medical (NASDAQ:ICCM) last issued its earnings results on Wednesday, April 3rd. The company reported ($0.07) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.01. IceCure Medical had a negative return on equity of 86.96% and a negative net margin of 453.76%. The business had revenue of $1.26 million during the quarter. During the same period in the previous year, the company earned ($0.11) EPS. Analysts anticipate that IceCure Medical will post -0.28 earnings per share for the current fiscal year.

Institutional Investors Weigh In On IceCure Medical

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Boothbay Fund Management LLC increased its stake in shares of IceCure Medical by 100.0% in the fourth quarter. Boothbay Fund Management LLC now owns 40,000 shares of the company’s stock valued at $62,000 after buying an additional 20,000 shares during the period. Bank of America Corp DE increased its stake in shares of IceCure Medical by 57.2% in the fourth quarter. Bank of America Corp DE now owns 55,388 shares of the company’s stock valued at $86,000 after buying an additional 20,159 shares during the period. UBS Group AG increased its stake in shares of IceCure Medical by 1,302.3% in the fourth quarter. UBS Group AG now owns 28,986 shares of the company’s stock valued at $45,000 after buying an additional 26,919 shares during the period. Finally, JPMorgan Chase & Co. bought a new stake in shares of IceCure Medical during the 2nd quarter valued at about $78,000. Institutional investors and hedge funds own 0.62% of the company’s stock.

IceCure Medical Company Profile

IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and commercialization of medical devices for cryoablation (freezing) of tumors in the human body. It offers ProSense system, a single probe system for the treatment of breast tumors; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology.